1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

AACR In Review: IDO Pushes Ahead, CTLA-4 Combo Lags Behind

 
• By Emily Hayes

Though momentum is building for IDO/PD-1 combos, it's still early days for new immunotherapy programs. Clinicians and investors weigh in on the latest data from the American Association for Cancer Research meeting and the state of the immuno-oncology field.

T-cells attacking cancer_1200x675

Merck & Co. Inc. arguably got a leg up in its bid to lead immuno-oncology coming out of the American Association for Cancer Research meeting, between the rise of IDO as a target and new data showing disappointing efficacy for Bristol-Myers Squibb Co.'s CTLA-4/PD-1 combination in melanoma compared to PD-1 monotherapy. But development activity is intense and it's unclear where it will all end.

At this year's AACR annual meeting, held April 1-6 in Washington D.C., Bristol reported that its Opdivo/Yervoy combination was superior...

More from Immuno-oncology

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Stock Watch: US CAR-T And Vaccine Actions: Net Negative For Access

 
• By Andy Smith

Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

More from Anticancer